Palivizumab is a monoclonal antibody used as a preventive measure against severe respiratory syncytial virus ([RSV](https://)) infections. It is specifically designed to provide passive immunity to infants who are at high risk for severe RSV disease. Palivizumab works by binding to the RSV virus and preventing it from entering cells and replicating.
